Gesynta Pharma reports positive results for GS-248 phase 1 study
Swedish pharma company Gesynta Pharma has reported positive results from the phase 1 clinical trial of GS-248, which is being developed for the treatment of microvascular diseases in chronic inflammatory conditions. The purpose of the early-stage clinical trial was to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of GS-248 after subjecting healthy subjects to […]